HY 05350
Alternative Names: HY-0005; HY-05350Latest Information Update: 02 Feb 2026
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Immunomodulators; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Research Cancer
Most Recent Events
- 22 Jul 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT07083323)
- 25 Apr 2025 Preclinical trials in Solid tumours in China (IV)
- 25 Apr 2025 Pharmacodynamics, Pharmacokinetics and adverse events data from preclinical studies were presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)